SHALBY
1 call
Concalls & earnings callsShalby Limited
Every summarised call, newest first. Latest is Q1 FY27, held 13 Aug 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →The quarter was about the hospital segment showing steady revenue growth while MedTech delivered strong top-line expansion, but both faced profitability pressure and management is focused on executing levers for margin improvement.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Consolidated Revenue | ₹338.6 Cr | 11.6% | |
| Consolidated EBITDA | ₹49 Cr | 1% | |
| Consolidated EBITDA Margin | 14.5% | — | |
| Consolidated PAT | ₹10.5 Cr | — |
Latest guidance
- Expect hospital EBITDA margin upward of 20% on a full-year basis.
- Shalby International occupancy expected to touch 30%+ from Q3/Q4 and achieve PBT positive in 6-9 months.
- Initiatives to reduce MedTech cash outflow by ~₹3 Cr/month, with further ~₹3 Cr/month reduction expected by Q4, leading to double-digit EBITDA margins.
- Expect group ROCE to improve to industry standard of 11% to 13% in 1 to 2 years.
- Gurgaon unit is not expected to incur tax expense for the next 2-3 years once PBT positive.
Said on the Q1 FY27 call.
Filed results
Reported quarterly history
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹275.63 Cr+27.6% YoY+3% QoQ | ₹-2.99 CrTurned loss-making YoYTurned loss-making QoQ | ₹-0.28Turned negative YoYTurned negative QoQ |
| Q2 FY25 | ₹267.54 Cr+12.4% YoY-4.1% QoQ | ₹2.36 Cr-91.4% YoY-84% QoQ | ₹0.22-91.4% YoY-83.9% QoQ |
| Q1 FY25 | ₹278.89 Cr+18.4% YoY+14.2% QoQ | ₹14.74 Cr-29.2% YoY-8.1% QoQ | ₹1.37-29.4% YoY-8.1% QoQ |
| Q4 FY24 | ₹244.23 Cr+22.7% YoY+13% QoQ | ₹16.04 Cr+15.4% YoY-15.8% QoQ | ₹1.49+15.5% YoY-16.3% QoQ |
| Q3 FY24 | ₹216.05 Cr+6.7% YoY-9.2% QoQ | ₹19.06 Cr+24.7% YoY-30.9% QoQ | ₹1.78+25.4% YoY-30.7% QoQ |
Call history
- Q1 FY27Cautious tone
The quarter was about the hospital segment showing steady revenue growth while MedTech delivered strong top-line expansion, but both faced profitability pressure and management is focused on executing levers for margin improvement.
- Consolidated Revenue
- ₹338.6 Cr11.6%
- Consolidated EBITDA
- ₹49 Cr1%